Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brand/Generic Settlement Reform Will Be Balancing Act For Congress

Executive Summary

Development of legislation to address settlements between brand and generic companies will need to ensure that commercial incentives remain for generic firms to challenge patents

You may also be interested in...

Brand/Generic Settlements Return To Capitol Hill

Apotex could make its case for scrapping first-to-file exclusivity during a hearing in Rep. Rush’s subcommittee.

Generic Firms Sanguine About New Congress, Preparing For Biogeneric Action

Among a number of potential congressional actions that could benefit the generic industry, generic manufacturers appear to be most bullish about the prospects for the establishment of a pathway for follow-on biologics

Brand/Generic Settlements Bill Clears Senate Cmte., Awaits Day On The Floor

After relatively smooth sailing through the Senate Judiciary Committee, legislation to prohibit "reverse payments" in brand/generic settlements now faces the challenge of securing floor-time for consideration by the full chamber

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts